Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer

Area of Science:

• Immunology
• Cancer Biology
• Cellular Therapy

Background:

• Dendritic cells (DCs) are key myeloid cells initiating adaptive immune responses.
• DCs are promising targets for cancer immunotherapy, but clinical translation remains challenging.
• Existing research presents complexities in DC development, subsets, and functional responses.

Purpose of the Study:

• To review current knowledge and challenges in targeting dendritic cells for cancer therapy.
• To propose advanced technological approaches for improved DC-directed cancer treatments.
• To advocate for standardized nomenclature for dendritic cell subsets.

Main Methods:

• Literature review of dendritic cell biology and therapeutic targeting.
• Analysis of emerging technologies, including multiomics approaches.
• Discussion of challenges in clinical trial design and interpretation.

Main Results:

• Despite their importance, effective clinical targeting of DCs in cancer has yielded limited success.
• Technological advancements offer new possibilities for understanding and manipulating DCs.
• A lack of standardized nomenclature complicates the identification and characterization of DC subsets.

Conclusions:

• Multiomics approaches are essential for advancing the directed targeting of dendritic cells in clinical settings.
• Standardized nomenclature is crucial for distinguishing distinct DC subsets and their functions.
• Future cancer immunotherapies may benefit from refined strategies based on a deeper understanding of DCs.